GSK PLC Statement: Zantac (ranitidine) litigation
2024年6月11日 - 2:27AM
RNS Regulatory News
RNS Number : 8704R
GSK PLC
10 June 2024
Issued: 10 June 2024, London
UK
Statement: Zantac (ranitidine) litigation - Kasza
case
GSK plc (LSE/NYSE: GSK) welcomes the
plaintiff's voluntary dismissal of the next Zantac case (Kasza),
which was scheduled to start trial in Illinois state court on 10
June 2024. GSK did not settle Ms. Kasza's claim and has not paid
anything in exchange for the voluntary dismissal.
Following the 16 epidemiological
studies looking at human data regarding the use of ranitidine, the
scientific consensus is that there is no consistent or reliable
evidence that ranitidine increases the risk of any
cancer.
GSK will continue to vigorously
defend itself and manage this litigation in the best interests of
the company and shareholders.
About GSK
GSK is a global biopharma company
with a purpose to unite science, technology, and talent to get
ahead of disease together. Find out more at gsk.com.
|
GSK
enquiries
|
|
|
|
|
Media:
|
Tim Foley
|
+44 (0) 20 8047 5502
|
(London)
|
|
|
Dan Smith
|
+44 (0) 20 8047 5502
|
(London)
|
|
|
Kathleen Quinn
|
+1 202 603 5003
|
(Washington DC)
|
|
|
Lyndsay Meyer
|
+1 202 302 4595
|
(Washington DC)
|
|
|
|
|
|
|
Investor Relations:
|
Nick Stone
|
+44 (0) 7717 618834
|
(London)
|
|
|
James Dodwell
|
+44 (0) 20 8047 2406
|
(London)
|
|
|
Mick Readey
|
+44 (0) 7990 339653
|
(London)
|
|
|
Josh Williams
|
+44 (0) 7385 415719
|
(London)
|
|
|
Camilla Campbell
|
+44 (0) 7803 050238
|
(London)
|
|
|
Steph Mountifield
|
+44 (0) 7796 707505
|
(London)
|
|
|
Jeff McLaughlin
|
+1 215 751 7002
|
(Philadelphia)
|
|
|
Frannie DeFranco
|
+1 215 751 4855
|
(Philadelphia)
|
Cautionary statement regarding forward-looking
statements
GSK cautions
investors that any forward-looking statements or projections made
by GSK, including those made in this announcement, are subject to
risks and uncertainties that may cause actual results to differ
materially from those projected. Such factors include, but are not
limited to, those described under Item 3.D "Risk factors" in GSK's
Annual Report on Form 20-F for 2023, and GSK's Q1 Results for
2024.
Registered in England & Wales:
No. 3888792
Registered Office:
980 Great West Road
Brentford, Middlesex
TW8 9GS
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
MSCEAXKEFASLEFA
Gsk (LSE:GSK)
過去 株価チャート
から 5 2024 まで 6 2024
Gsk (LSE:GSK)
過去 株価チャート
から 6 2023 まで 6 2024
